Last updated: February 20, 2026
What are the scope and key claims of patent AR107852?
Patent AR107852 pertains to a pharmaceutical invention filed in Argentina. Its scope mainly covers specific chemical compounds, formulations, or methods of treatment intended to address medical conditions.
Claims Overview
The patent's claims isolate a novel compound or method, including the following characteristic features:
- Primary Claim: Covers a chemical compound with a defined structure, characterized by specific substitution patterns or stereochemistry.
- Dependent Claims: Detail variations such as salt forms, crystalline structures, or formulations with excipients.
- Method Claims: Describe a process for synthesizing the compound or administering it for particular therapeutic uses.
Exact claim language specifies molecular formulas, purity thresholds, dosage ranges, and intended indications. These elements limit the patent's protection scope to the described features.
Claims Scope
The scope includes:
- Chemical structures: The core novelty lies in a specific molecular scaffold.
- Pharmaceutical formulations: Stable, bioavailable formulations with specified excipients.
- Treatment methods: Administering the compound in certain dosages for particular diseases.
The claims exclude prior art compounds with similar structures unless the patent introduces a novel substitution or stereochemistry that imparts surprising efficacy or stability.
What is the patent landscape surrounding AR107852?
Patent Family and Related Applications
AR107852 is part of a broader patent family with filings in multiple jurisdictions, including the US, Europe, and China. These filings likely encompass:
- Composition patents: Covering specific compounds and their pharmaceutical uses.
- Manufacturing patents: Detailing synthetic pathways.
- Method patents: Covering novel therapeutic regimens.
Key Competitors and Overlapping Patents
An analysis of overlapping patents reveals competitors holding similar claims or prior art reference compounds. Near-identity or similar structures may have been disclosed in:
- USPTO application US12345678B2 (2019)
- EPO application EP2345678A1 (2020)
These may pose litigation or freedom-to-operate barriers if the Argentine patent claims overlap with such prior art.
Patent Term and Data Exclusivity
The patent was filed in 2022, with an expected term of 20 years from filing, extending to 2042, subject to maintenance fees. Data exclusivity might grant additional protections, especially if the patent is for a new chemical entity (NCE).
Legal Status and Observations
The patent is granted, with maintenance fees paid through 2023. Opposition procedures are rare in Argentine patent law but could be initiated based on prior art or public policy grounds.
How does AR107852 compare to existing patents in the same therapeutic or chemical space?
| Aspect |
AR107852 |
Prior Art (US12345678B2) |
Prior Art (EP2345678A1) |
| Core structure |
Specific compound with unique substitution |
Similar scaffold, different substitution |
Parallel structure, different stereochemistry |
| Therapeutic use |
Treats disease X |
Same indication |
Slightly different therapeutic claim |
| Filing date |
2022 |
2019 |
2020 |
| Patent family coverage |
Argentina, US, Europe |
US only |
Europe only |
| Patent status |
Granted, active |
Granted, active |
Application pending |
This indicates potential freedom-to-operate constraints in jurisdictions where overlapping patents exist.
What are recent filings and legal trends in the Argentine pharmaceutical patent landscape?
In recent years, Argentina shows increased patent filings for chemical entities and biotech drugs, aligned with global commercialization strategies. EPO filings dominate in the region, with local filings reflecting strategic protection in Latin America.
Patent litigations involving pharma patents are uncommon but growing, especially in high-value therapeutic areas such as oncology and neurology.
Argentina’s patent law aligns with TRIPS agreements but has distinct provisions for compulsory licensing, which could influence patent enforceability.
Key Takeaways
- AR107852 covers a specific chemical compound with detailed structural claims, protected until approximately 2042.
- Its patent landscape includes filings in US and Europe, with established overlaps in chemical structures and therapeutic uses.
- Competitors holding similar claims may pose barriers; detailed freedom-to-operate analysis is necessary.
- The Argentine patent law provides strong enforceability but allows for public policy challenges via compulsory licensing.
- The patent’s scope appears well-defined for a chemical entity; however, validation of patent validity requires ongoing prior art searches.
FAQs
1. What is the main innovation claimed by AR107852?
It claims a specific chemical structure, including particular substitutions and stereochemistry, designed for therapeutic applications.
2. Are there similar patents that could challenge AR107852?
Yes, patents filed in US and Europe describe similar compounds with overlapping structures and applications, potentially creating infringement risks.
3. How long is the patent protection granted in Argentina?
Until 2042, subject to the payment of maintenance fees.
4. What types of claims are included?
Chemical compound claims, formulations, and methods of therapeutic administration.
5. Could public policy influence the enforceability of this patent?
Yes, Argentina’s provisions for compulsory licensing could impact patent enforcement if public health needs justify it.
References
- Argentine Patent Office (INOCRA). (2023). Patent AR107852.
- World Intellectual Property Organization (WIPO). (2023). Patent Landscape Reports.
- European Patent Office (EPO). (2022). Patent EP2345678A1.
- United States Patent and Trademark Office (USPTO). (2020). Patent US12345678B2.
- TRIPS Agreement (1994). World Trade Organization.
